Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023:190:211-244.
doi: 10.1007/978-3-031-45654-1_7.

The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer

Affiliations

The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer

Vinh The Nguyen et al. Cancer Treat Res. 2023.

Abstract

The switch/sucrose non-fermenting (SWI/SNF) chromatin remodeling complex is a global regulator of gene expression known to maintain nucleosome-depleted regions at active enhancers and promoters. The mammalian SWI/SNF protein subunits are encoded by 29 genes and 11-15 subunits including an ATPase domain of either SMARCA4 (BRG1) or SMARCA2 (BRM) are assembled into a complex. Based on the distinct subunits, SWI/SNF are grouped into 3 major types (subfamilies): the canonical BRG1/BRM-associated factor (BAF/cBAF), polybromo-associated BAF (PBAF), and non-canonical BAF (GBAF/ncBAF). Pan-cancer genome sequencing studies have shown that nearly 25% of all cancers bear mutations in subunits of the SWI/SNF complex, many of which are loss of function (LOF) mutations, suggesting a tumor suppressor role. Inactivation of SWI/SNF complex subunits causes widespread epigenetic dysfunction, including increased dependence on antagonistic components such as polycomb repressor complexes (PRC1/2) and altered enhancer regulation, likely promoting an oncogenic state leading to cancer. Despite the prevalence of mutations, most SWI/SNF-mutant cancers lack targeted therapeutic strategies. Defining the dependencies created by LOF mutations in SWI/SNF subunits will identify better targets for these cancers.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Mittal P, Roberts CWM (2020) The SWI/SNF complex in cancer–biology, biomarkers and therapy. Nat Rev Clin Oncol 17:435–448 - PMC - DOI - PubMed
    1. Centore RC, Sandoval GJ, Soares LMM, Kadoch C, Chan HM (2020) Mammalian SWI/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies. Trends Genet 36:936–950 - DOI - PubMed
    1. Jones CA, Tansey WP, Weissmiller AM (2022) Emerging themes in mechanisms of tumorigenesis by SWI/SNF subunit mutation. Epigenet Insights 15:25168657221115656 - PMC - PubMed
    1. McBride MJ, Kadoch C (2018) Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities. J Pathol 244:638–649 - PMC - DOI - PubMed
    1. Wei D, Goldfarb D, Song S, Cannon C, Yan F, Sakellariou-Thompson D, Emanuele M, Major MB, Weissman BE, Kuwahara Y (2014) SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development. Mol Cancer Res 12:1574–1585 - PMC - DOI - PubMed

LinkOut - more resources